

## Updates In Glomerular Disease: Additional Resources

### Current Therapy for IgA Nephropathy

Citation: Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1785-1794. doi:10.1681/ASN.2011030221

Link: <https://pubmed.ncbi.nlm.nih.gov/21903997/>

### Guidelines: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Citation: Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

Link: <https://pubmed.ncbi.nlm.nih.gov/34556256/>

### The Testing Randomized Trial

Citation: Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888-1898. doi:10.1001/jama.2022.5368

Link: <https://pubmed.ncbi.nlm.nih.gov/35579642/>

### DUET Phase 2 Randomized Study

Citation: Trachtman H, Nelson P, Adler S, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745-2754. doi:10.1681/ASN.2018010091

Link: <https://pubmed.ncbi.nlm.nih.gov/30361325/>

### DUPLEX Phase 3 Randomized Trial

Citation: Komers R, Diva U, Inrig JK, Loewen A, Trachtman H, Rote WE. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020;5(4):494-502. doi:10.1016/j.ekir.2019.12.017

Link: <https://pubmed.ncbi.nlm.nih.gov/32274453/>

### PROTECT Phase 3 Randomized Trial (ongoing)

Citation: Wong M, Barratt J, Komers R, Mercer A, Rosenberg N. MO209: Baseline characteristics of adults enrolled in the ongoing phase 3 randomized, double-blind, active-control trial of sparsentan for the treatment of immunoglobulin A nephropathy (PROTECT). Nephrol Dial Transplant.

2022;37(Supplement\_3):gfac067.008. doi.org/10.1093/ndt/gfac067.008

Link: [https://academic.oup.com/ndt/article/37/Supplement\\_3/gfac067.008/6578479](https://academic.oup.com/ndt/article/37/Supplement_3/gfac067.008/6578479)

**Additional Articles:**

**Avacopan for the Treatment of ANCA-Associated vasculitis**

Citation: Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599-609.

doi:10.1056/NEJMoa2023386

Link: <https://www.nejm.org/doi/full/10.1056/NEJMoa2023386>

**Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis**

Citation: Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232.

doi:10.1056/NEJMoa0909905

Link: <https://www.nejm.org/doi/full/10.1056/nejmoa0909905>